$INO
INOVIO PHARMACEUTICALS, INC.

2024 Q3 Form 10-Q Financial Statement

#000105572624000046 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $100.8K
YoY Change -100.0% -55.41%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.614M $10.21M
YoY Change -13.25% -24.52%
% of Gross Profit
Research & Development $18.73M $23.09M
YoY Change 20.84% -2.75%
% of Gross Profit
Depreciation & Amortization $419.3K $491.5K
YoY Change -34.48% -35.88%
% of Gross Profit
Operating Expenses $27.35M $33.30M
YoY Change -23.91% -10.65%
Operating Profit -$27.35M -$33.20M
YoY Change -23.08% -10.38%
Interest Expense $2.762M $952.2K
YoY Change 781.0% 203.76%
% of Operating Profit
Other Income/Expense, Net -$579.8K $7.571K
YoY Change -20416.01% -100.53%
Pretax Income -$25.17M -$32.24M
YoY Change -25.83% -9.28%
Income Tax
% Of Pretax Income
Net Earnings -$25.17M -$32.24M
YoY Change -25.77% -9.19%
Net Earnings / Revenue -31993.31%
Basic Earnings Per Share -$0.89 -$1.19
Diluted Earnings Per Share -$0.89 -$1.19
COMMON SHARES
Basic Shares Outstanding 25.96M shares 25.91M shares
Diluted Shares Outstanding 28.14M shares 27.20M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.80M $110.4M
YoY Change -49.37% -43.35%
Cash & Equivalents $21.69M $34.39M
Short-Term Investments $63.12M $76.03M
Other Short-Term Assets $4.617M $5.366M
YoY Change -9.47% 65.47%
Inventory
Prepaid Expenses
Receivables $1.863M $1.774M
Other Receivables $0.00 $0.00
Total Short-Term Assets $91.28M $117.6M
YoY Change -47.77% -42.17%
LONG-TERM ASSETS
Property, Plant & Equipment $4.092M $4.511M
YoY Change -27.36% -28.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.644M $2.320M
YoY Change -11.86% -16.56%
Other Assets $566.4K $585.9K
YoY Change -6.43% -12.14%
Total Long-Term Assets $15.78M $16.24M
YoY Change -13.94% -45.43%
TOTAL ASSETS
Total Short-Term Assets $91.28M $117.6M
Total Long-Term Assets $15.78M $16.24M
Total Assets $107.1M $133.8M
YoY Change -44.56% -42.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.386M $6.409M
YoY Change 38.09% -38.12%
Accrued Expenses $18.11M $19.97M
YoY Change -7.11% -5.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $23.50M $26.40M
YoY Change -46.24% -49.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.02M $10.66M
YoY Change -10.53% -8.92%
Total Long-Term Liabilities $10.02M $10.66M
YoY Change -10.53% -8.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.50M $26.40M
Total Long-Term Liabilities $10.02M $10.66M
Total Liabilities $33.52M $37.06M
YoY Change -38.99% -41.79%
SHAREHOLDERS EQUITY
Retained Earnings -$1.700B -$1.700B
YoY Change 6.25% 6.25%
Common Stock $26.05K $25.96K
YoY Change -90.34% -90.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $73.54M $96.74M
YoY Change
Total Liabilities & Shareholders Equity $107.1M $133.8M
YoY Change -44.56% -42.59%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$25.17M -$32.24M
YoY Change -25.77% -9.19%
Depreciation, Depletion And Amortization $419.3K $491.5K
YoY Change -34.48% -35.88%
Cash From Operating Activities -$27.44M -$28.21M
YoY Change -5.73% -12.7%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $452.2K
YoY Change 1790.59%
Acquisitions
YoY Change
Other Investing Activities $14.08M $10.42M
YoY Change -355.96% -80.68%
Cash From Investing Activities $14.08M $9.966M
YoY Change -355.96% -81.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 660.6K 33.03M
YoY Change -5.62% 1045.85%
NET CHANGE
Cash From Operating Activities -27.44M -28.21M
Cash From Investing Activities 14.08M 9.966M
Cash From Financing Activities 660.6K 33.03M
Net Change In Cash -12.70M 14.79M
YoY Change -62.53% -39.57%
FREE CASH FLOW
Cash From Operating Activities -$27.44M -$28.21M
Capital Expenditures $0.00 $452.2K
Free Cash Flow -$27.44M -$28.66M
YoY Change -5.73% -11.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-32237098 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35534533 usd
us-gaap Net Income Loss
NetIncomeLoss
-62706969 usd
us-gaap Net Income Loss
NetIncomeLoss
-76183850 usd
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083333
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083333
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083333
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
33297675 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
37267068 usd
us-gaap Operating Expenses
OperatingExpenses
64782644 usd
us-gaap Operating Expenses
OperatingExpenses
81334189 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33196913 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-37041097 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-64681882 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-80993275 usd
CY2024Q2 us-gaap Interest Income Operating
InterestIncomeOperating
1307358 usd
CY2023Q2 us-gaap Interest Income Operating
InterestIncomeOperating
2168233 usd
us-gaap Interest Income Operating
InterestIncomeOperating
2807648 usd
us-gaap Interest Income Operating
InterestIncomeOperating
4375404 usd
CY2024Q2 us-gaap Interest Expense Operating
InterestExpenseOperating
0 usd
CY2023Q2 us-gaap Interest Expense Operating
InterestExpenseOperating
313488 usd
us-gaap Interest Expense Operating
InterestExpenseOperating
177833 usd
us-gaap Interest Expense Operating
InterestExpenseOperating
626976 usd
CY2024Q2 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-334294 usd
CY2023Q2 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
156745 usd
ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-460312 usd
ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
773384 usd
CY2024Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-20820 usd
CY2023Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
922941 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
480057 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
4141156 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7571 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1427867 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-674647 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3853543 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-32237098 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35534533 usd
us-gaap Net Income Loss
NetIncomeLoss
-62706969 usd
us-gaap Net Income Loss
NetIncomeLoss
-76183850 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.50
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27197802 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27197802 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22029486 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22029486 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25244657 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25244657 shares
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-376 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
32403 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2294 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13322 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-108089 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-59338 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9773 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32250420 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35642998 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62733904 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76176371 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
117349129 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5225133 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-174248 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2525433 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-30469871 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-46016 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
32403 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
94441963 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17059668 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16146397 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-172454 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1514053 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-32237098 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13322 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
96739207 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
222362756 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-424704 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3809003 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40649317 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
117862 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1918 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
199213682 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2915179 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-32292 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2917997 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35534533 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-108089 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-376 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
169371568 usd
us-gaap Net Income Loss
NetIncomeLoss
-62706969 usd
us-gaap Net Income Loss
NetIncomeLoss
-76183850 usd
us-gaap Depreciation
Depreciation
916019 usd
us-gaap Depreciation
Depreciation
1410649 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
145417 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
672336 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
739469 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1984444 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4039486 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6727000 usd
ino Non Cash Interest Income Expense
NonCashInterestIncomeExpense
355654 usd
ino Non Cash Interest Income Expense
NonCashInterestIncomeExpense
-93489 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1154822 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
2402451 usd
us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
-692557 usd
us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
-3853543 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-21930 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-334297 usd
ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-460312 usd
ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
773384 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
480057 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
4141156 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-631563 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6621990 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-48237 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-41191898 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-19400 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-17154 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2362045 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-43955799 usd
ino Increase Decrease In Accrued Clinical Trial Expense
IncreaseDecreaseInAccruedClinicalTrialExpense
3134266 usd
ino Increase Decrease In Accrued Clinical Trial Expense
IncreaseDecreaseInAccruedClinicalTrialExpense
-4421691 usd
ino Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
-458376 usd
ino Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
-1406066 usd
ino Increase Decreasein Deferred Grant Funding Current
IncreaseDecreaseinDeferredGrantFundingCurrent
-87489 usd
ino Increase Decreasein Deferred Grant Funding Current
IncreaseDecreaseinDeferredGrantFundingCurrent
1185913 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56969306 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68979134 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
29359747 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
106741680 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
85196528 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
173898007 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
487832 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
320898 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6071000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
55348949 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
72906429 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
16415000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
16146397 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22284801 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2915179 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
67675 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
ino Proceeds From Payments For Stock Options Exercised And Exercise Of Warrants Net Of Tax Withholdings
ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings
-414377 usd
ino Proceeds From Payments For Stock Options Exercised And Exercise Of Warrants Net Of Tax Withholdings
ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings
-456996 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21669496 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2458183 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32403 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2294 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20081542 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6383184 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14310862 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46329359 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34392404 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52712543 usd
us-gaap Interest Paid Net
InterestPaidNet
533487 usd
us-gaap Interest Paid Net
InterestPaidNet
533487 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued1
StockIssued1
14000000 usd
us-gaap Nature Of Operations
NatureOfOperations
Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the “Company” or “INOVIO”) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body’s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA delivery devices are designed to optimally deliver the plasmids into the body's cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a life-long, rare disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in August 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div>
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-32200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-62700000 usd
CY2024Q2 ino Working Capital
WorkingCapital
91200000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1700000000 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
110400000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5200000 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5500000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
79498907 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11252 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3481043 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
76029116 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
134873427 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
36647 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3927161 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
130982913 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
300 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
500 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
2000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
693000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
200 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
500 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
1500000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
3900000 usd
CY2024Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-21000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
480000 usd
CY2023Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
923000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
4100000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
22 position
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3500000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
19 position
CY2024Q2 ino Prepaid Clinical Expenses Current
PrepaidClinicalExpensesCurrent
2341285 usd
CY2023Q4 ino Prepaid Clinical Expenses Current
PrepaidClinicalExpensesCurrent
3410442 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3024575 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1983223 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5365860 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5393665 usd
CY2024Q2 ino Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
22000 usd
CY2023Q4 ino Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
1500000 usd
ino Grant Liability
GrantLiability
2300000 usd
CY2023 ino Grant Liability
GrantLiability
4300000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25963544 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25963544 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22793075 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-32237098 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35534533 usd
CY2024Q2 ino Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
25461260 shares
CY2023Q2 ino Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
22029486 shares
CY2024Q2 ino Incremental Common Shares Attributable To Basic And Dilutive Effect Of Pre Funded Warrants
IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants
1736542 shares
CY2023Q2 ino Incremental Common Shares Attributable To Basic And Dilutive Effect Of Pre Funded Warrants
IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants
0 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27197802 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27197802 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22029486 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22029486 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
us-gaap Net Income Loss
NetIncomeLoss
-62706969 usd
us-gaap Net Income Loss
NetIncomeLoss
-76183850 usd
ino Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
24376386 shares
ino Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
21784343 shares
ino Incremental Common Shares Attributable To Basic And Dilutive Effect Of Pre Funded Warrants
IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants
868271 shares
ino Incremental Common Shares Attributable To Basic And Dilutive Effect Of Pre Funded Warrants
IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants
0 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25244657 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25244657 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21784343 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21784343 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.50
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1783353 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1783353 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1823765 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1823765 shares
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3700000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.96
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.28
CY2024Q2 ino Share Based Compensation Arrangement By Share Based Payment Award Threshold Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage
1.50
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1696000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3467000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3555000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2955000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2310000 usd
CY2024Q2 ino Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2132000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16115000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3135000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12980000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2322000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10658000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2024Q2 us-gaap Lease Cost
LeaseCost
521000 usd
us-gaap Lease Cost
LeaseCost
1400000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
856000 usd
us-gaap Lease Cost
LeaseCost
1700000 usd
CY2019Q4 ino Lessee Operating Lease Number Of Agreements To Sublease
LesseeOperatingLeaseNumberOfAgreementsToSublease
2 agreement
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
ino-20240630_g1.jpg Edgar Link pending
ino-6302410qex312.htm Edgar Link pending
ino-63024x10qex311.htm Edgar Link pending
ino-63024x10qex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
ino-20240630_pre.xml Edgar Link unprocessable
ino-20240630_lab.xml Edgar Link unprocessable
ino-20240630_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0001055726-24-000046-index-headers.html Edgar Link pending
0001055726-24-000046-index.html Edgar Link pending
0001055726-24-000046.txt Edgar Link pending
0001055726-24-000046-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ino-20240630.htm Edgar Link pending
ino-20240630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ino-20240630_cal.xml Edgar Link unprocessable
ino-20240630_def.xml Edgar Link unprocessable